Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, dose escalation study in women with primary, non-recurrent
breast cancer undergoing surgery. AVB-620 will be administered prior to surgery.